AQUINOX PHARMACEUTICALS, INC Form DEFA14A March 27, 2015

### **SCHEDULE 14A INFORMATION**

### Proxy Statement Pursuant to Section 14(a) of the

### **Securities Exchange Act of 1934**

(Amendment No. )

Filed by the Registrant x

Filed by a Party other than the Registrant "

Check the appropriate box:

- " Preliminary Proxy Statement
- " Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- " Definitive Proxy Statement
- x Definitive Additional Materials
- " Soliciting Material Pursuant to § 240.14a-12

**Aquinox Pharmaceuticals, Inc.** 

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box)

- x No fee required.
- " Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  - 1. Title of each class of securities to which transaction applies:

# Edgar Filing: AQUINOX PHARMACEUTICALS, INC - Form DEFA14A

2.	Aggregate number of securities to which transaction applies:
3.	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Se forth the amount on which the filing fee is calculated and state how it was determined):
4.	Proposed maximum aggregate value of transaction:
5.	Total fee paid:
Fee paid previously with preliminary materials.	
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.	
6.	Amount Previously Paid:
7.	Form, Schedule or Registration Statement No.:
8.	Filing Party:
9.	Date Filed:

# Edgar Filing: AQUINOX PHARMACEUTICALS, INC - Form DEFA14A

## Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting of

### AQUINOX PHARMACEUTICALS, INC.

To Be Held On:

May 11, 2015, at 1:00 p.m. at

the offices of Cooley LLP, 1700 Seventh Avenue, Suite 1900, Seattle, Washington 98101-1355

**COMPANY NUMBER** 

ACCOUNT NUMBER

#### CONTROL NUMBER

This is not a ballot. You cannot use this notice to vote. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. If you want to receive a paper or e-mail copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery, please make the request as instructed below before May 1, 2015.

Please visit http://www.astproxyportal.com/ast/18777/, where the following materials are available for view:

Notice of Annual Meeting of Stockholders

**Proxy Statement** 

Form of Electronic Proxy Card

Annual Report on Form 10-K

TO REQUEST MATERIAL:TELEPHONE: 888-Proxy-NA (888-776-9962) 718-921-8562 (for international callers)

### Edgar Filing: AQUINOX PHARMACEUTICALS, INC - Form DEFA14A

E-MAIL: info@amstock.com

WEBSITE: http://www.amstock.com/proxyservices/requestmaterials.asp

TO VOTE:

**ONLINE:** To access your online proxy card, please visit <u>www.voteproxy.com</u> and follow the on-screen instructions or scan the QR code with your smartphone. You may enter your voting instructions at www.voteproxy.com up until 11:59 PM Eastern Time the day before the meeting date.

**IN PERSON:** You may vote your shares in person by attending the Annual Meeting. For directions, please call the offices of Cooley LLP at 206-452-8700.

**TELEPHONE:** To vote by telephone, please visit <u>www.voteproxy.com</u> to view the materials and to obtain the toll free number to call.

MAIL: You may request a card by following the instructions above.

- 1. Nominees for Election for a Three-Year Term Expiring at the 2018 Annual Meeting:
- 2. To ratify the selection by the Audit Committee of the Board of Directors of Deloitte LLP as the independent registered public accounting firm of Aquinox Pharmaceuticals, Inc. for its fiscal year ending December 31, 2015.

David Main

Sean Nolan